E. Schulze

640 total citations
17 papers, 486 citations indexed

About

E. Schulze is a scholar working on Hepatology, Oncology and Hematology. According to data from OpenAlex, E. Schulze has authored 17 papers receiving a total of 486 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Hepatology, 5 papers in Oncology and 4 papers in Hematology. Recurrent topics in E. Schulze's work include Hepatocellular Carcinoma Treatment and Prognosis (6 papers), Ovarian cancer diagnosis and treatment (3 papers) and Virus-based gene therapy research (2 papers). E. Schulze is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (6 papers), Ovarian cancer diagnosis and treatment (3 papers) and Virus-based gene therapy research (2 papers). E. Schulze collaborates with scholars based in Germany, United Kingdom and France. E. Schulze's co-authors include M. M. Heiss, Barbara Schmalfeldt, Pauline Wimberger, Horst Lindhofer, Michael A. Ströhlein, Rainer Kimmig, Harald Sommer, Jacobus Pfisterer, Thomas Gottwald and Stylianos Michalakis and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Annals of Oncology.

In The Last Decade

E. Schulze

16 papers receiving 464 citations

Peers

E. Schulze
Ileana Bortolomai Italy
K. Yoshinaga Japan
Kunzang Chosdol India
Yasmin Issa Germany
Carla Danussi Italy
Van de Ven Wj Belgium
Mira Park South Korea
Arvind Chaudhry United States
Mario Regazzoni Italy
Sandra J. Yokota United States
Ileana Bortolomai Italy
E. Schulze
Citations per year, relative to E. Schulze E. Schulze (= 1×) peers Ileana Bortolomai

Countries citing papers authored by E. Schulze

Since Specialization
Citations

This map shows the geographic impact of E. Schulze's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Schulze with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Schulze more than expected).

Fields of papers citing papers by E. Schulze

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Schulze. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Schulze. The network helps show where E. Schulze may publish in the future.

Co-authorship network of co-authors of E. Schulze

This figure shows the co-authorship network connecting the top 25 collaborators of E. Schulze. A scholar is included among the top collaborators of E. Schulze based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. Schulze. E. Schulze is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Bećirović, Elvir, Sybille Böhm, Ong Nam Phuong Nguyen, et al.. (2016). In Vivo Analysis of Disease-Associated Point Mutations Unveils Profound Differences in mRNA Splicing of Peripherin-2 in Rod and Cone Photoreceptors. PLoS Genetics. 12(1). e1005811–e1005811. 21 indexed citations
2.
Eisen, David, Mirko Wagner, Susanne Koch, et al.. (2015). TET3 Is Recruited by REST for Context-Specific Hydroxymethylation and Induction of Gene Expression. Cell Reports. 11(2). 283–294. 115 indexed citations
3.
Michalakis, Stylianos, Susanne Koch, Vithiyanjali Sothilingam, et al.. (2014). Gene Therapy Restores Vision and Delays Degeneration in the CNGB1−/− Mouse Model of Retinitis Pigmentosa. Advances in experimental medicine and biology. 801. 733–739. 29 indexed citations
4.
Heiss, M. M., Michael A. Ströhlein, Carsten Bokemeyer, et al.. (2014). The Role of Relative Lymphocyte Count as a Biomarker for the Effect of Catumaxomab on Survival in Malignant Ascites Patients: Results from a Phase II/III Study. Clinical Cancer Research. 20(12). 3348–3357. 18 indexed citations
5.
Wimberger, Pauline, Hélène Gilet, M. M. Heiss, et al.. (2012). Deterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone. Annals of Oncology. 23(8). 1979–1985. 54 indexed citations
6.
Schmalfeldt, Barbara, Hélène Gilet, Michael Hennig, et al.. (2012). Quality of life in patients with malignant ascites and after treatment with catumaxomab: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone. Geburtshilfe und Frauenheilkunde. 72(4). 1 indexed citations
7.
Gonschior, A. K., Hélène Gilet, Michael Hennig, et al.. (2011). Quality of Life in Patients With Malignant Ascites and Ascites Symptoms After Treatment With Catumaxomab: Results From a Multicenter Phase II/III Study Comparing Paracentesis Plus Catumaxomab With Paracentesis Alone. mediaTUM (Technical University of Munich). 2 indexed citations
8.
Berek, Jonathan S., L M Parker, Leslie R. DeMars, et al.. (2011). Catumaxomab treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: A phase II study.. Journal of Clinical Oncology. 29(15_suppl). 5048–5048. 5 indexed citations
9.
10.
Heiss, M. M., Carsten Bokemeyer, David Arnold, et al.. (2011). The role of relative lymphocyte count as a new biomarker for the effect of catumaxomab on overall survival in patients with malignant ascites: Follow-up results from a phase ll/lll study.. Journal of Clinical Oncology. 29(15_suppl). 2512–2512. 2 indexed citations
11.
Bokemeyer, C., et al.. (2009). Safety of catumaxomab: Cytokine-release-related symptoms as a possible predictive factor for efficacy in a pivotal phase II/III trial in malignant ascites. Journal of Clinical Oncology. 27(15_suppl). 3036–3036. 7 indexed citations
12.
Burges, Alexander, Pauline Wimberger, Carolin Kümper, et al.. (2007). Effective Relief of Malignant Ascites in Patients with Advanced Ovarian Cancer by a Trifunctional Anti-EpCAM × Anti-CD3 Antibody: A Phase I/II Study. Clinical Cancer Research. 13(13). 3899–3905. 208 indexed citations
13.
Egger, Dietmar, Christine Günther, W Helbig, & E. Schulze. (1998). Pre‐treatment of peripheral blood progenitor cells with macrophage inflammatory protein‐1α induces prolonged survival of early progenitor cells over 6 weeks of long‐term culture. British Journal of Haematology. 103(4). 1181–1183.
14.
Schulze, E., Rainer Krahl, Karin Thalmeier, & W Helbig. (1995). Detection of bcr-abl mRNA in single progenitor colonies from patients with chronic myeloid leukemia by PCR: comparison with cytogenetics and PCR from uncultured cells.. PubMed. 23(14). 1649–54. 15 indexed citations
15.
Elstner, Elena, et al.. (1985). Stromal Progenitor Cells in Bone Marrow of Patients with Aplastic Anemia. Hämatologie und Bluttransfusion. 29. 168–171. 4 indexed citations
16.
Elstner, Elena, et al.. (1983). Proliferation and Maturation of Hemopoietic Cells from Patients with Preleukemia and Aplastic Anemia in Agar and Diffusion Chamber Cultures. Hämatologie und Bluttransfusion. 111(3). 358–361. 3 indexed citations
17.
Schulze, E.. (1955). Neuere Untersuchungen über die Ätiologie der Leukämie. DMW - Deutsche Medizinische Wochenschrift. 80(22). 868–868. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ileana Bortolomai Breakdown of academic impact, for papers by K. Yoshinaga Breakdown of academic impact, for papers by Kunzang Chosdol Breakdown of academic impact, for papers by Yasmin Issa Breakdown of academic impact, for papers by Carla Danussi Breakdown of academic impact, for papers by Van de Ven Wj Breakdown of academic impact, for papers by Mira Park Breakdown of academic impact, for papers by Arvind Chaudhry Breakdown of academic impact, for papers by Mario Regazzoni Breakdown of academic impact, for papers by Sandra J. Yokota
Rankless by CCL
2026